title: Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy.
authors: Chadi
authors: C
authors: Al-Nawakil
authors: Jerome
authors: J
authors: Tamburini
authors: Valerie
authors: V
authors: Bardet
authors: Nicolas
authors: N
authors: Chapuis
authors: Edward
authors: E
authors: Bourry
authors: Christian
authors: C
authors: Roux
authors: Sophie
authors: S
authors: Park
authors: Sylvain
authors: S
authors: Choquet
authors: François
authors: F
authors: Dreyfus
authors: Didier
authors: D
authors: Bouscary
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D003907:Dexamethasone / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007952:Leukemia, Plasma Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000627:therapeutic use; D012074:Remission Induction / Q000379:methods; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D004317:Doxorubicin